🔴 Nurix Therapeutics is trading 6.3% down in pre-market as the cause remains unclear

Nurix Therapeutics is trading at $21.55, down 6.26%, with no verified overnight company announcement directly explaining the pre-market decline.

• Search results include an October 5 headline about a Gilead collaboration extension and a $10 million fee, but available evidence does not establish it as a fresh company announcement or link it to the selloff.
• Broad futures were only modestly lower and do not clearly explain the move; the cause remains uncertain.
• Market data show Nurix is due to report Q3 results October 8 after the close.